Collaborations & Alliances

CytomX Achieves $15M AbbVie Milestone

Advances CD71-Targeting Probody Drug Conjugate into GLP toxicology studies  

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CytomX Therapeutics, Inc., a biopharma company developing Probody therapeutics for the treatment of cancer, has advanced CX-2029, a Probody drug conjugate (PDC) targeting CD71, into GLP toxicology studies, a key step to filing an Investigational New Drug (IND) application in 2018. CytomX will receive a $15 million milestone payment from AbbVie as part of the companies 2016 strategic oncology collaboration. “CD71 is highly attractive for delivery of cytotoxic payloads to cancer cells, but its ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters